Tigis

×

Varování

JUser: :_load: Nelze nahrát uživatele s ID: 64
pondělí, 03 leden 2011 17:35

Psychiatrie 4/2010

Napsal(a)

OBSAH

EDITORIAL ............................................................................................................................... 167
OBSAH .....................................................................................................................................168
PÙVODNÍ PRÁCE
Dita Kalnická, Jiří Masopust, Kateřina Konupčíková, Radovan Malý, Jan Bažant
Kardiometabolické riziko u nemocných schizofrenií ...................................................................... 170
PŘEHLEDNÉ ČLÁNKY
Pavel Martínek, Aleš Bartoš
Dotazníky k hodnocení běžných činností u pacientů s Alzheimerovou nemocí .................................. 175
Karina Verébová, Jiří Horáček
Dysbindin – funkční kandidátní gen pro schizofrenii ...................................................................... 181

VZDĚLÁVÁNÍ
Jan Libiger
Klinická psychopatologie poruch vìdomí ....................................................................................... 192
FÓRUM ČESKÉ NEUROPSYCHOFARMAKOLOGICKÉ SPOLEČNOSTI
Jaromír Švestka
Olanzapin ve formě dlouhodobě působících intramuskulárních injekcí ................................................ 201

Jiří Patočka, Kamil Kuča
Pozoruhodná molekula AF267B a Alzheimerova nemoc ................................................................. 209

Jiří Horáček
Farmakologické odlišnosti Risperidonu a Paliperidonu ER: role hydroxylace
a lékové formy v antipsychotickém účinku .................................................................................... 212

Jaromír Švestka, Cyril Höschl, Martin Anders, Luboš Janù,
Jiří Masopust, Pavel Mohr, Radovan PŘikryl
Možnosti použití aripiprazolu v léčbì bipolární afektivní poruchy.
Konsensus expertù v české republice ........................................................................................... 218
ZPRÁVY .....................................................................................................................................225
Přečetli jsme za Vás .................................................................................................................. 225
NOVÉ KNIHY ............................................................................................................................. 226

CONTENTS

EDITORIAL ................................................................................................................................. 167
CONTENTS ................................................................................................................................ 168
ORIGINAL PAPERS
Dita Kalnická, JiŘí Masopust, KateŘina Konupčíková, Radovan Malý, Jan Bažant
Cardiometabolic Risk in Patients with Schizophrenia ...................................................................... 170
REVIEWS
Pavel Martínek, Aleš Bartoš
Questionnaires for assessment of activities of daily living
in patients with dementia ............................................................................................................. 175
Karina Verébová, Jiří Horáček
Dysbindin – a functional candidate gene for schizophrenia .............................................................. 181
Jan Libiger
Clinical psychopathology of the conciousness disturbances ............................................................ 192
FORUM OF THE CZECH NEUROPSYCHOPHARMACOLOGICAL SOCIETY
Jaromír Švestka
Olanzapine in the form of long-acting intramuscular injections ........................................................ 201
Jiří Patočka, Kamil Kuča
Remarkable molecule AF267B and Alzheimer's disease ................................................................ 209
Jiří Horáček
Pharmacological differences between Risperidone and Paliperidone ER:
the role of hydroxylation and drug formulation in the antipsychotic effect .......................................... 212
Jaromír Švestka, Cyril Höschl, Martin Anders, Luboš Janù,
JiŘí Masopust, Pavel Mohr, Radovan PŘikryl
Possibilities of aripiprazole use in the treatment of bipolar affective disorder.
expert consensus in the Czech Republic ...................................................................................... 218
COMMUNICATIONS ................................................................................................................... 225
We have read for you .................................................................................................................. 225
NEW BOOKS ............................................................................................................................ 226

pátek, 12 listopad 2010 10:03

Psychiatrie suppl 1/2010

Napsal(a)

OBSAH

EDITORIAL .............................................................. 1

OBSAH .................................................................. 2

LAUDACE ................................................................ 4

PROGRAM ................................................................ 5

PLENÁRNÍ PŘEDNÁŠKY .................................................... 11

ODBORNÁ SYMPOZIA
ANTIPSYCHOTIKA I
Role 5-HT1A receptoru v patofyziologii a léčbě schizofrenie a závislostí 12
První epizoda schizofrenie z pohledu biologické psychiatrie
a klinické neuropsychofarmakologie (sympozium Společnosti
pro biologickou psychiatrii) .......................................... 13


Psychosociální intervence jako nezbytný doplněk farmakoterapie
schizofrenie: Výsledky v ČR ........................................... 14


ANTIPSYCHOTIKA II
Kardiometabolické riziko u nemocných schizofrenií ..................... 16


„Off label“ použití antipsychotik druhé generace ...................... 17

ANTIDEPRESIVA
Léčba antidepresivy ................................................... 18

Predikce terapeutického účinku v psychofarmakologii ................... 18


EXPERIMENTÁLNÍ A KLINICKÁ PSYCHOFARMAKOLOGIE
Experimentální psychofarmakologie ve studiu
glutamátergního systému ............................................... 20

Neuropsychiatrická úskalí dopaminergní transmise ...................... 21

Formativní procesy maturace CNS – geneze neuropsychických
poruch a strategie optimálního vývoje ................................. 22


FARMAKOTERAPIE ÚZKOSTI A OSOBNOSTI
Od obsese ke stereotypiím (princip obsese
u psyciatricko-neurologických poruch) ................................. 23

Hraniční porucha osobnosti a její léčba ............................... 24


FARMAKOTERAPIE AKUTNÍCH STAVÙ
Akutní stavy v neuropsychiatrii a jejich léčba ........................ 25

Násilí a duševní nemoc: epidemiologie, farmakoterapie ................. 27


NEUROBIOLOGIE KOGNITIVNÍCH JEVÙ
fMRI v hodnocení kognitivních jevů v neuropsychiatrii ................. 27

Novější indikace psychofarmak v psychiatrii dětí, adolescentů a dospělých 28

Estrogeny a poruchy příjmu potravy a kognitivní funkce ................ 30


WORKSHOPY
Sedmero hlavních hříchů IV. - pýcha ................................... 33

Lži, zpropadené lži a statistika ...................................... 34

Posttraumatická stresová porucha jako komorbidní onemocnění
duševních poruch ...................................................... 34

Léčba chronické insomnie .............................................. 34

Diagnostika a léčba katatonních příznaků .............................. 35

Kritický rozbor dvou článků o psychofarmakologii ...................... 35

Kdy, jak a proč mezi sebou kombinovat psychofarmaka ................... 35


NOVÝ VÝZKUM
Nový preklinický výzkum ............................................... 37

Nový klinický výzkum I. (úzkostné a afektivní poruchy) ................ 38

Nový klinický výzkum II (ostatní poruchy) ............................. 39


VÝVĚSKOVÁ SDĚLENÍ
Základní výzkum I. (psychotické poruchy a ostatní) .................... 41

Klinický výjkum I. (psychotické poruchy) .............................. 44

Základní výzkum II. (neuroprotektivita, deprese) ...................... 45

Klinický výzkum II. (úzkost, deprese) ................................. 47

Základní výzkum III. (návykové látky) ................................. 50

Klinický výzkum III. (problémové oblasti farmakoterapie) .............. 52


OSTATNÍ SDĚLENÍ ....................................................... 55

FIREMNÍ SYMPÓZIA ...................................................... 56

JMENNÝ REJSTŘÍK ....................................................... 57

INFORMACE ............................................................. 60


 

CONTENTS

EDITORIAL .............................................................. 1
CONTENTS ............................................................... 2
LAUDATION .............................................................. 4
PROGRAMME .............................................................. 5
PLENARY LECTURES ...................................................... 11

SCIETIFIC SYMPOSIA
ANTIPSYCHOTICS I
The role of 5-HT1A receptor in pathophysiology and treatment
of schizophrenia and addiction ........................................ 12

First-episode schizophrenia from the perspective of biological psychiatry
and clinical neuropsychopharmacology .................................. 13

Psychosocial interventions as an inevitable supplement
to schizophrenia treatment: Results from the Czech Republic .......... 14

ANTIPSYCHOTICS II
Cardiometabolic Risks in Schizophrenia Patients ....................... 16

„Off-label“ Use of Second-Generation Antipsychotics ................... 17

ANTIDEPRESSANTS
Antidepressant Treatment .............................................. 18

Prediction of a Therapeutic Response in Psychopharmacology ............ 18

EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY
Experimental Psychopharmacology in the Research of Glutamatergic System 20

Neuropsychiatric Pitfalls of Dopaminergic Transmission ................. 21
Formative Processes of the CNS Maturation – A Genesis of
Neuropsychiatric Disorders and Strategy of Optimal Development ........ 22

PHARMACOTHERAPY OF ANXIETY AND PERSONALITY DISORDERS
From Obsessions to Stereotypes (A Principle of Obsession
in Psychiatric and Neurologic Disorders) .............................. 23

Borderline Personality Disorder and its Treatment ..................... 24

PHARMACOTHERAPY OF ACUTE CONDITIONS
Acute Conditions in Neuropsychiatry and their Treatment ............... 25

Violence in Mental Illness: Epidemiology and Pharmacology ............. 27

NEUROBIOLOGY OF COGNITION
fMRI for studying cognitive processing in neuropsychiatry ............. 27

New indications of psychotropics in child, adolescent, and
adult psychiatry ...................................................... 28

Estrogens, eating disorders and cognitive functions ................... 30

WORKSHOPS
Seven deadly sins IV: Pride ........................................... 33

Lies, Damn Lies, and Statistics ....................................... 34

Comorbidity of PTSD and schizophrenia ................................. 34

Treatment of Chronic Insomnia ......................................... 34

Diagnosis and Treatment of Catatonic Symptoms .......................... 35

Critical Analysis of Two Psychopharmacology Papers .................... 35

When, how and why to combine psychotropic drugs ....................... 35

NEW RESEARCH
New Preclinical Research .............................................. 37

New Clinical Research I (Anxiety and Affective Disorders) ............. 38

New Clinical Research II (Other Disorders) ............................ 39

POSTER SESSIONS
Prelinical Research I (Psychotic Disorders and Others) ................ 41
Clinical Research I (Psychotic Disorders) ............................. 44
Prelinical Research II (Neuroprotection, Depression) .................. 45
Clinical Research II (Anxiety, Depression) ............................ 47
Prelinical Research III (Addictive Substances) ........................ 50
Clinical Research III (Problem Issues in Pharmacotherapy) ............. 52
VARIOUS ................................................................55
SPONSORED SATELLITE SYMPOSIA .......................................... 56
NAME INDEX ............................................................ 57
INFORMATIONS .......................................................... 60

středa, 10 listopad 2010 12:06

Psychiatrie 2010 Suppl. 2

Napsal(a)

 

CONTENTS

EDITORIAL ......................................................................................................................... 1
CONTENTS ........................................................................................................................ 3
 

ORIGINAL PAPERS
Lucie Surá, Vlastimil Zíma, Filip Touška, Viktorie Vlachová
Ankyrin receptor – ion channel activated by psychoactive drugs:
its relation to the mechanisms of nociception ................................................................................ 5

Monika Vrajová, Jiøí Horáèek, Jan Klaschka
Expression of GluN1C2 subunit of NMDA receptor in hippocampus
of patients suffered from schizophrenia – post mortem study ...................................................... 10

Zdena Krištofíková, Daniela Øípová
Asymmetry in activities of nitric oxide synthases in the rat brain and animal
modeling of neurodevelopmental or neurodegenerative diseases .................................................... 12

David Levèík, Daniel Klement, Tereza Nekováøová, Karel Valeš, Aleš Stuchlík
The NMDA-receptor antagonist MK-801 impairs recognition
of position of a distant object ....................................................................................................... 15

Hana Tejkalová, Šárka Rùžièková, Jan Klaschka
Effect of antipsychotic chronic administration on cytokine expression
in neuroinfectious model of schizophrenia ............................................................................... 19

Vìra Bubeníková-Valešová, Jana Puskarèíková, Monika Vrajová, Jiøí Horáèek
Alteration in subunits expression of N-methyl-D-aspartate receptor after
application of serotonin-1a receptor partial agonists (buspirone, tandospirone)
in hippocampus and frontal cortex in rats ................................................................................ 22

Karel Valeš, Lukáš Rambousek, Aleš Stuchlík, Hana Chodounská, Ladislav Vyklický
Comparison of Effects of Systemic Application of Non-Competitive
and Use-Dependent NMDA Antagonists on the Locomotor Activity
and Cognitive Functions in the Laboratory Rat ...................................................................... 26

Marie Pometlová, Kateryna Deykun, Romana Šlamberová
Investigation of methamphetamine effect on anxiety and learning
in the test of elevated plus-maze .................................................................................................. 31

Tomáš Páleníèek, Vìra Bubeníková-Valešová, Jiøí Horáèek,
Michaela Fujáková, Ingmar Gorman
The effect mGlu2/3 receptor agonist LY379268
on behavior in serotonin model of psychosis – the pilot study ...................................................... 35

Tereza Nekováøová, Jan Nedvídek, Daniel Klement, Richard Rokyta, Jan Bureš
Cognitive function of macaques: mental transformation of geometrical stimuli .............................. 39

Aleš Bartoš, Petr Zach, Jaroslav Tintìra, Ibrahim Ibrahim, Daniela Øípová
Simple classification of white matter changes on brain MRI in the elderly ........................................ 44

Jaroslav Tintìra, Ibrahim Ibrahim, Aleš Bartoš, Daniela Øípová
Characterization of the patients with Alzheimer disease using SWI:
detection of micro-bleedings and tissue changes in basal ganglia .............................................. 48

Kamil Vlèek, Zuzana Nedìlská, Jan Laczó, Martin Vyhnálek, Jakub Hort

Real space navigation in the development of Alzheimer’s disease ............................................... 52

Anna Yamamotová, Pavel Hrabák, Petr Høíbek, Richard Rokyta
Nociception in humans with tattoo and different motivation to pain experience ............................. 56

Martin Bareš, Tomáš Novák, Martin Brunovský
Depressive episode of bipolar affective disorder – the early change
of prefrontal cordance as a possible predictor of treatment response ................................................ 61

Tomáš Novák, Eva Gunde, Miloslav Kopeèek, Tomáš Hájek, Matthias Schmidt, Cyril Höschl
White matter hyperintensities in offspring of bipolar parents – results from
czech sample ............................................................................................................................. 66

Michal Raszka, Ján Praško, Jana Kopøivová, Jiøí Horáèek, Martin Brunovský
Electrophysiological correlate of dissociations in obsessive-compulsive disorder –
a pilot study ............................................................................................................................... 70

Lucie Bankovská Motlová, Eva Dragomirecká, Jan Èermák, David Holub
Relapse frequency and quality of life in day-treatment programme for psychotic
disorders: one-year outcomes ........................................................................................................ 73

Marek Preiss, Radka Èermáková, Mabel Rodriguez
Rehabilitation of cognitive functions on-line: possibilities
of the cognifit programme .............................................................................................................. 77

Mabel Rodriguez, Pavel Mohr, Lucie Bankovská Motlová, Radka Èermáková,
Tomáš Novák, Marek Preiss
Short-term efficacy of cognitive remediation of cognitive
deficit in schizophrenia ................................................................................................................... 81

úterý, 09 listopad 2010 13:41

Psychiatrie 02/2010

Napsal(a)
úterý, 09 listopad 2010 10:10

Psychiatrie 03/2010

Napsal(a)
úterý, 02 listopad 2010 09:54

Psychiatrie 01/2010

Editorial .............................................................................................................................. 1
Obsah ................................................................................................................................. 2
Původní práce
Miroslav Kudláček
Stojedenáctka – protivník nebo spojenec? ................................................................................ 4

Tomáš Novák, Miloslav Kopeček, Tomáš Hájek, Jiří Horáček, Cyril Höschl
Morfometrie založená na voxelech u postižených a nepostižených
potomků rodičů s bipolární afektivní poruchou ........................................................................... 7

Přehledné články
Maroš Matiaško
Možnosti predikcie násilného jednania u páchateľa s duševnou poruchou .................................. 12

Zdena Krištofiková, Jiří Patočka, Daniela Řípová
Stereospecifické interakce peptidů amyloidu β ........................................................................ 18

Marek Preiss
Krátkodobá efektivita trénování paměti .................................................................................... 22

Martin Bareš, Tomáš Novák
Kombinace antidepresiv v akutní léčbě rezistentní depresivní
poruchy: přehled randomizovaných studií ................................................................................ 27

Anna Slavíčková, Martin Brunovský, Pavel Mohr
Kognitivní evokované potenciály v klinické praxi a experimentu .................................................. 34

Vzdělávání
Michaela Hůlková, Ladislav Hosák
Psychické změny u pacientů s jaterním onemocněním.............................................................  41

Fórum České neuropsychofarmakologické společnosti
Michaela Fujáková, Tomáš Páleníček, Věra Bubeníková-Valešová, Jiří Horáček
Ketamin. Klinické a experimentální využití a zneužívání ............................................................ 47

Dopisy, diskuze, ohlasy
Filip Španiel, Lucie Bankovská Motlová
Program Coopera 2009 .......................................................................................................... 54

Zprávy ................................................................................................................................  55
Přečetli jsme za Vás ........................................................................................................... 59

Nové knihy .......................................................................................................................... 63

 

Editorial ................................................................................................................................ 1
Contents ............................................................................................................................... 2
Original Papers
Miroslav Kudláček
The fellow or the ally? .............................................................................................................. 4

Tomáš Novák, Miloslav Kopeček, Tomáš Hájek, Jiří Horáček, Cyril Höschl
Voxel-based morphometry of affected and unaffected offspring
of parents with bipolar affective disorder...................................................................................... 7

Reviews
Maroš Matiaško
Possibilities of violent acts risk assessment of offender with mental disorder ............................... 12

Zdena Krištofiková, Jiří Patočka, Daniela Řípová
Stereospecific interactions of amyloid b peptides....................................................................... 18

Marek Preiss
Short-term effectivity of memory training ................................................................................... 22

Martin Bareš, Tomáš Novák
The combinations of antidepressants in the acute treatment
of resistant depression: a review of randomized trials................................................................. 27

Anna Slavíčková, Martin Brunovský, Pavel Mohr
Cognitive evoked potentials in clinical practice and in experiment ............................................... 34

CME
Michaela Hůlková, Ladislav Hosák
Psychiatric symptoms in patients suffering from liver diseases ................................................... 41

Forum of the Czech Neuropsychopharmacological Society
Michaela Fujáková, Tomáš Páleníček, Věra Bubeníková-Valešová, Jiří Horáček
Ketamine. Clinical and experimental use and abuse .................................................................. 47

Correspondence
Filip Španiel, Lucie Bankovská Motlová
Programme Coopera 2009....................................................................................................... 54

Communications ................................................................................................................. 55
We have read for you ......................................................................................................... 59

New Books .......................................................................................................................... 63

úterý, 02 listopad 2010 08:23

Psychiatrie 3/2010

Editorial ...................................................................................................................... 115

Obsah ......................................................................................................................... 116

Původní práce

Lenka Pleštilová, Lucie Bankovská Motlová
Dotazníkové šetření mezi absolventy preventivně edukačního programu
proti relapsu psychózy (PREDUKA) (Krátké sdělení) ....................................................... 118

Přehledné články

Marek Preiss, Miroslava Benešová
Od tréninku paměti k tréninku plasticity .......................................................................... 121

Michal Raszka, Adam Chalupníček, Ján Praško
Depersonalizace a derealizace z klinického hlediska ........................................................127

Pavel Kalvach, Zdeněk Kalvach
Demence na prahu 20. století: Praha vs. Frankfurt vs. Mnichov ......................................... 135

Kazuistiky

Jiří Jošt
Oční pohyby a dyslexie .................................................................................................. 141

Vzdělávání

Petr Hejzlar, Martin Halíř, Marek Fiala
Komunitní přístup v péči o dlouhodobě duševně nemocné ................................................... 146

Fórum České neuropsychofarmakologické společnosti

Pavel Mohr
Iloperidon: variace na obehrané téma anebo první aplikace
personalizované medicíny v psychiatrii?............................................................................. 153

Zprávy
Přečetli jsme za Vás ...................................................................................................... 159

Informace ...................................................................................................................... 163

Nové knihy ..................................................................................................................... 165

 

Editorial .......................................................................................................................... 115

Contents ..........................................................................................................................116

Original Papers

Lenka Pleštilová, Lucie Bankovská Motlová
Preventive educational programme for psychosis relapse prevention (PREDUCA):
Field questionnaire survey among participants .................................................................... 118

Reviews

Marek Preiss, Miroslava Benešová
From memory to plasticity training .................................................................................... 121

Michal Raszka, Adam Chalupníček, Ján Praško
Depersonalization and derealization from the clinical point of view ........................................ 127

Pavel Kalvach, Zdeněk Kalvach
Dementia on the threshold of the 20th century:
Prague vs. Frankfurt vs. Munich ........................................................................................ 135

Case report

Jiří Jošt
Eye movements and dyslexia ............................................................................................141

CME

Petr Hejzlar, Martin Halíř, Marek Fiala
Community approach in care for longterm mentally ill .........................................................  146

Forum of the Czech Neuropsychopharmacological Society

Pavel Mohr
Iloperidone: an old tune variation or the first implementation
of personalized medicine into psychiatry? ........................................................................... 153

Communications
We have read for you .........................................................................................................  159

Informations....................................................................................................................... 163

New Books .....................................................................................................................   165